Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis

Idiopathic pulmonary fibrosis is a progressive fibrotic disorder with no cure that is characterized by deterioration of lung function. Current FDA-approved drugs for IPF delay the decline in lung function, but neither reverse fibrosis nor significantly improve overall survival. SHP-1 deficiency resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Shiao-Ya, Lu, Ya-Ting, Chen, Shih-Yu, Hsu, Chiung-Fang, Lu, Yi-Chun, Wang, Cheng-Yi, Huang, Kun-Lun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249559/
https://www.ncbi.nlm.nih.gov/pubmed/37291088
http://dx.doi.org/10.1038/s41419-023-05876-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249559/
https://www.ncbi.nlm.nih.gov/pubmed/37291088
http://dx.doi.org/10.1038/s41419-023-05876-z

Ejemplares similares